The bad news is it was on bardoxolone. Tweetorial catch-up here.
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
The bad news is it was on bardoxolone. Tweetorial catch-up here.
✳️ #TenTweetNephJC ✳️
— Nephrology Journal Club (@NephJC) January 28, 2023
This week CARDINAL - the largest ever RCT in patients with Alport Syndrome 🧵👇 pic.twitter.com/wrAxJoz1GJ